NeuroPace has launched the RNS Tablet, a new device intended to aid physicians in reviewing data and personalizing therapy for patients being treated with the RNS System.
The RNS System, a closed-loop brain-responsive neurostimulation system, was approved by the Food and Drug Administration in 2013 as an adjunctive therapy for reducing the frequency of seizures in patients ≥18 years of age with partial onset seizures who have undergone diagnostic testing that localized no more than 2 epileptogenic foci, are refractory to ≥2 antiepileptic drugs, and currently have frequent and disabling seizures. A surgical procedure places electrodes at the source of the seizure.
The new RNS Tablet integrates the NeuroPace Programmer and online Patient Data Management System (PDMS) into one interface. The Tablet’s display includes more customizable information to display trends in neurostimulator and electrocorticographic data. In addition, there are now less steps needed to adjust settings.
“Having access to patient data in a centralized, easy-to-use interface is invaluable when monitoring patient progress and personalizing therapy,” said Dr. Vikram Rao, Epileptologist at UCSF Medical Center.
The RNS Tablet will be unveiled at the AES Annual Meeting, being held in Washington D.C. from December 1–5. Attendees can take part in hands-on workshops of the new device.
For more information visit Neuropace.com.